Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Pilot Study of Exendin-4 in Alzheimer s Disease
Authors not listed
National Institute on Aging (NIA) · 2010
Abstract
Background:
Exendin-4 (or Exenatide) is a medication currently used to treat diabetes that has shown promising results in animal and cellular models of Alzheimer's disease. It is possible that Exendin-4 may be a treatment for Alzheimer's disease, which involves the gradual deterioration and death of neurons. Researchers are interested in studying the safety and comparing the effects of Exendin-4 with placebo on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.
Objectives:
To determine the safety and tolerability of twice daily administration of Exendin-4, as well as to acquire preliminary evidence for effects on cognitive performance, clinical progression of dementia, various chemicals measured in blood and cerebrospinal fluid, and brain MRI, in individuals with early-stage Alzheimer's disease or mild cognitive impairment.
Eligibility:
Individuals at least 60 years of age who have objective evidence of early-stage Alzheimer's disease or mild cognitive impairment in screening testing.
Design:
* Participants will be screened.
* Following the telephone screening, two in-person screening visits to determine eligibility.
* The screening visit will involve a medical history and neurological examination, tests of memory and cognition, a lumbar puncture, collection of blood and saliva samples, and brain Magnetic Resonance Imagine (MRI) studies. Participants will be required to appoint a Durable Power of Attorney for research and medical care during this protocol.
* Eligible participants will be divided into two groups (double-blind randomization). One group will receive Exendin-4 SC twice daily, and the other will receive a placebo. Participants will keep a medication diary and will be scheduled for additional study visits 1 and 2 weeks after the start of the treatment.
* Participants will have regular followup visits with blood tests, cognitive tests, imaging studies, and other examinations 6, 12, and 18 months after the start of the treatment. Another lumbar puncture may be performed optionally at the 18-month followup visit.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Anonymous. (2010). A Pilot Study of Exendin-4 in Alzheimer s Disease. <em>National Institute on Aging (NIA)</em>. https://clinicaltrials.gov/study/NCT01255163
Vancouver
Anonymous. A Pilot Study of Exendin-4 in Alzheimer s Disease. National Institute on Aging (NIA). 2010.
BibTeX
@misc{anon2010APilot,
title = {A Pilot Study of Exendin-4 in Alzheimer s Disease},
author = {Anonymous},
journal = {National Institute on Aging (NIA)},
year = {2010},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Massachusetts General Hospital 2025
Open access · US-GOV
Grit Against Cognitive Decline in Aging and Preclinical Alzheimer's Disease
Georgetown University 2007
Open access · US-GOV
DC Longitudinal Study on Aging and Specimen Bank
Florida Atlantic University 2007
Open access · US-GOV
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
National Institute on Aging (NIA) 2026
Open access · US-GOV
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease
National Institute on Aging (NIA) 2015
Open access · US-GOV
Resveratrol and Cardiovascular Health in the Elderly: The Reache Trial
Posit Science Corporation 2004
Open access · US-GOV